A detailed history of Buckingham Strategic Partners transactions in Abb Vie Inc. stock. As of the latest transaction made, Buckingham Strategic Partners holds 30,264 shares of ABBV stock, worth $5.96 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
30,264
Previous 32,206 6.03%
Holding current value
$5.96 Million
Previous $5.86 Million 11.49%
% of portfolio
0.15%
Previous 0.18%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $300,602 - $351,035
-1,942 Reduced 6.03%
30,264 $5.19 Million
Q1 2024

May 15, 2024

BUY
$159.82 - $182.1 $3.65 Million - $4.16 Million
22,854 Added 244.38%
32,206 $5.86 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $1.81 Million - $2.04 Million
-13,148 Reduced 58.44%
9,352 $1.45 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $1.84 Million - $2.13 Million
13,783 Added 158.12%
22,500 $3.35 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $128,667 - $160,117
971 Added 12.54%
8,717 $1.17 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $450,749 - $519,105
3,117 Added 67.34%
7,746 $1.23 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $1.98 Million - $2.37 Million
-14,305 Reduced 75.55%
4,629 $748,000
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $1.8 Million - $2.07 Million
13,432 Added 244.13%
18,934 $2.54 Million
Q2 2022

Aug 12, 2022

SELL
$137.62 - $174.96 $36,606 - $46,539
-266 Reduced 4.61%
5,502 $843,000
Q1 2022

May 10, 2022

SELL
$131.98 - $163.75 $159,563 - $197,973
-1,209 Reduced 17.33%
5,768 $934,000
Q4 2021

Feb 10, 2022

BUY
$107.43 - $135.93 $749,539 - $948,383
6,977 New
6,977 $946,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $348B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Buckingham Strategic Partners Portfolio

Follow Buckingham Strategic Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Buckingham Strategic Partners, based on Form 13F filings with the SEC.

News

Stay updated on Buckingham Strategic Partners with notifications on news.